With sales of its leading Hepatitis C treatments down, Gilead Sciences will...

...launch generic versions of Harvoni and Epclusa, which will reportedly be available at much lower prices. Harvoni currently holds preferred status for 11% of covered lives, with Epclusa at 16%. Harvoni is classified as a specialty drug for 29% of covered lives, with Epclusa at 30%.